Cargando…
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study
Rett syndrome is a rare, genetic neurodevelopmental disorder. Trofinetide is a synthetic analog of glycine–proline–glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome. In this phase 3 study (https...
Autores principales: | Neul, Jeffrey L., Percy, Alan K., Benke, Timothy A., Berry-Kravis, Elizabeth M., Glaze, Daniel G., Marsh, Eric D., Lin, Tim, Stankovic, Serge, Bishop, Kathie M., Youakim, James M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287558/ https://www.ncbi.nlm.nih.gov/pubmed/37291210 http://dx.doi.org/10.1038/s41591-023-02398-1 |
Ejemplares similares
-
Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome
por: Glaze, Daniel G., et al.
Publicado: (2019) -
A review of the Rett Syndrome Behaviour Questionnaire and its utilization in the assessment of symptoms associated with Rett syndrome
por: Percy, Alan K., et al.
Publicado: (2023) -
A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects
por: Darwish, Mona, et al.
Publicado: (2022) -
Trofinetide—a new chapter in rett syndrome’s treatment
por: Furqan, Muhammad
Publicado: (2023) -
Multisystem comorbidities in classic Rett syndrome: a scoping review
por: Fu, Cary, et al.
Publicado: (2020)